CC
EGRX

Corton Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Corton Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,917
Closed -$62.3K – 686
2023
Q4 		$62.3K Buy
+11,917
New +$118K 0.02% 558

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Corton Capital's EGRX Position: Q1 2024 in Review

Corton Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 11,917 shares — an estimated $62.3K sold.

Corton Capital first reported a position in EGRX in Q4 2023 and held it in 1 quarter. The position peaked at $62.3K in Q4 2023. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

  • Corton Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Corton Capital sold 11,917 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $62.3K.
  • Corton Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2023 and held it in 1 quarter.
  • Corton Capital's Eagle Pharmaceuticals, Inc. position peaked at $62.3K in Q4 2023.
  • 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Corton Capital's 13F filing for Q1 2024, filed 15 May 2024.